TITLE

Irbesartan was renoprotective in patients with type 2 diabetes, hypertension, and microalbuminuria

AUTHOR(S)
Rabbat, Christian G.
PUB. DATE
May 2002
SOURCE
ACP Journal Club;May/Jun2002, Vol. 136 Issue 3, p82
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Comments on a study on the effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Health risks posed by type 2 diabetes mellitus; Benefits from irbesartan.
ACCESSION #
8856083

 

Related Articles

  • Prevalence of microalbuminuria and risk factor analysis in type 2 diabetes patients in Albania: the need for accurate and early diagnosis of diabetic nephropathy. Pasko, N.; Toti, F.; Strakosha, A.; Thengjilli, E.; Shehu, A.; Dedej, T.; Ylli, A.; Thereska, N. // Hippokratia;2013, Vol. 17 Issue 4, p337 

    Background: Microalbuminuria is often the first sign of renal dysfunction in diabetes. This study aimed to investigate the prevalence of microalbuminuria in Albanian type 2 diabetes patients and its association with other cardiovascular risk factors. Methods: Three hundred and twenty-one...

  • Four studies find linagliptin effective as monotherapy, add-on in adults with type 2 diabetes. Costa, Samantha; Fisher, Stacey L.; Foster, Melissa // Endocrine Today;Nov2012, Vol. 10 Issue 11, p36 

    The article reports on four studies which found that linagliptin administered alone or in combination with other diabetes medications, and as an add-on to basal insulin therapy is effective in adults with type 2 diabetes and diabetic nephropathy.

  • The Effect of Milk Thistle Extract in the Treatment of Diabetic Nephropathy. Rezvanian, Hassan; Kachuei, Ali; Mirzapour, Ali // Journal of Isfahan Medical School;3/28/2011, Vol. 28 Issue 124, p1 

    Background: Milk thistle has antioxidative effects and may improve renal performance. Our study investigated whether Milk thistle improve renal performance in patients with type II diabetes mellitus nephropathy. Methods: In this clinical trial study, after ethics committee approval, 65 Patients...

  • Periostin as a Tissue and Urinary Biomarker of Renal Injury in Type 2 Diabetes Mellitus. Satirapoj, Bancha; Tassanasorn, Surat; Charoenpitakchai, Mongkon; Supasyndh, Ouppatham // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Background: Improving the early detection of diabetic nephropathy remains a great challenge in disease management. Periostin is a marker of renal tubular injury and related to progressive kidney injury in animal models of chronic kidney disease. The clinical implications of urinary periostin...

  • Limitations of HbA[sub1c] in diabetes control.  // Pulse;3/24/2003, Vol. 63 Issue 12, p88 

    Discusses the limitations of the HbA[sub 1c] in aiding the treatment of type 2 diabetes. Method of monitoring the effectiveness of therapy in diabetes; Clinical advantages of measuring fructosamine level.

  • New diabetes treatments may be on horizon.  // Diabetes in the News;Nov/Dec94, Vol. 13 Issue 6, p3 

    Reports on studies regarding new therapies for type II diabetes. Food and Drug Administration's (FDA) pending approval of an oral agent called metformin; Studies on thiazoles and vanadates; Mechanism of action of tolrestat; Use of combination drug approach in diabetes-related impotence; Use of...

  • Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes.  // Formulary;Feb2010, Vol. 45 Issue 2, p34 

    An abstract of the article "Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes," by Ashley Krause and Jennifer Kirwin is presented.

  • Managing Obesity as First-Line Therapy for Diabetes Mellitus. Kelley, David E. // Nutrition in Clinical Care;Jan/Feb98 Supplement 1, Vol. 1 Issue 1, p38 

    Focuses on the management of obesity for the treatment of type 2 diabetes mellitus in the United States. Improvement of weight loss in obese patients; Impact of weight loss on the clinical efficacy of concominant pharmacologic therapy; Reduction of skeletal muscles insulin resistance.

  • Newer, controlled-release glipizide is superior to its conventional form.  // Modern Medicine;Mar95, Vol. 63 Issue 3, p53 

    Presents an abstract of the article `Comparative Efficacy of a Once-daily Controlled-Release Formulation of Glipizide and Immediate-Release Glipizide in Patients With NIDDM,' by M. Berelowitz, C. Fischette et al dated December 1994.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics